Durvalumab/Tremelimumab
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Durvalumab/Tremelimumab, covering 2023-03-21 to 2023-03-21. Get the full timeline:
Most recent: Clinical Trial Update: Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients. [Phase 2]